Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Study:

AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF)

Rationale:

n/a

Purpose:

This study will test the effectiveness of warfarin in patients with IPF. Approximately 256 patients will be randomized 1:1 to either warfarin or placebo. Patients will return at week 1 for a safety review and every 16 weeks for 48 weeks. The primary endpoint in the study is the time to either death, non-bleeding/non-elective hospitalization, or a drop of greater than 10% in forced vital capacity (FVC) from baseline.

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
Idiopathic Pulmonary Fibrosis Drug: warfarin
Drug: placebo
Phase 3

Verified by Duke University April, 2013

Sponsored by: Duke University
Information provided by: Duke University
ClinicalTrials.gov identifier: NCT00957242

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Galen Toews, MD., Study Chair
Gail Weinmann, MD., Study Director
Kevin Brown, MD., Principal Investigator
Rob Kaner, MD., Principal Investigator
Talmadge King, MD., Principal Investigator
Joe Lasky, MD., Principal Investigator
James Loyd, MD., Principal Investigator
Fernando Martinez, MD., Principal Investigator
Imre Noth, MD., Principal Investigator
Ganesh Raghu, MD., Principal Investigator
Jesse Roman, MD., Principal Investigator
Jay Ryu, MD., Principal Investigator
Joseph Lynch, MD., Principal Investigator
Kevin Anstrom, PhD., Principal Investigator
Joao deAndrade, MD., Principal Investigator
Jeffrey Chapman, MD., Principal Investigator
Lake Morrison, MD., Principal Investigator
Michael Kallay, MD., Principal Investigator
Steven Sahn, MD., Principal Investigator
Marilyn Glassberg, MD., Principal Investigator
Milton Rossman, MD., Principal Investigator
John Fitzgerald, MD., Principal Investigator
Mary Beth Scholand, MD., Principal Investigator
Neil Ettinger, MD., Principal Investigator
Danielle Antin-Ozerkis, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site